Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 16   

Articles published

KYTH 32.54 -0.31 (-0.94%)
price chart
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
KYTHERA Biopharmaceuticals, Inc. KYTH, +0.15% today announced that on September 26, 2014, the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase an aggregate of 12,500 shares of the ...
Related articles »  
Kythera Biopharmaceuticals Inc. (KYTH) Jumps 5.49% on October 8
Kythera Biopharmaceuticals Inc. (KYTH) was among the biggest gainers on the Russell 2000 for October 8 as the stock popped 5.49% to $32.86, representing a gain of $1.71 per share.
Related articles »  
Insider Selling: Kythera Biopharmaceuticals CEO Unloads 3826 Shares of Stock ...
Analysts expect that Kythera Biopharmaceuticals will post $-3.34 earnings per share for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
Insider Selling: Nathaniel E. David Unloads 1350 Shares of Kythera ...  WKRB News
Related articles »  
Kythera Biopharmaceuticals Director Sells $44010 in Stock (KYTH)
Analysts expect that Kythera Biopharmaceuticals will post $-3.34 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription ...
Related articles »  
Eye Catching Stocks: Vale S.A. (NYSE:VALE), FireEye (NASDAQ:FEYE), China ...
On last trading day Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) moved down -1.24% to close at $35.76. KYTH is -36.55% away from its 52 week high and is moving 21.22% ahead of its 52 week low.
Active Stocks to Watch: Vodafone Group Plc (ADR) (NASDAQ:VOD), CBD ...
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) has 2.20% insider ownership while its institutional ownership stands at 33.20%.
A Newer Nifty Fifty State Index: Replacements Rule!
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) was projected to net $453.86 based on 1yr. target price estimates from five analysts plus dividends less $20 broker fees.
Provectus Biopharmaceuticals Sees Large Decrease in Short Interest (PVCT)
Provectus Biopharmaceuticals Inc logo Provectus Biopharmaceuticals (NYSE:PVCT) was the recipient of a significant drop in short interest in August.
Related articles »  
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...
17, 2014-- Gilead Sciences , Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated ...
Related articles »